Scale-up centers for innovative biologic small-batch production

01Overview and value chain#

Markers EC: Shared pilot- and demonstration-scale biomanufacturing testbeds and training | OECD: Biopharmaceutical manufacturing innovation | Regulator: FDA (US), EMA (EU)

Scale-up centers for innovative biologic small-batch production operate shared pilot- and demonstration-scale facilities that let a developer prove out a manufacturing process before committing capital to a dedicated commercial-scale plant. NIIMBL, the US National Institute for Innovation in Manufacturing Biopharmaceuticals, announced 8 new technology and workforce projects in May 2026, including an enhanced end-to-end manufacturing testbed for fast, flexible drug-substance manufacturing using state-of-the-art process equipment, sensors and controls. BioMADE expanded its biomanufacturing pilot-plant network with a new $40M facility in Iowa — its third in a national network — and finalized a $132M national-security investment in a demonstration-scale biomanufacturing facility in Minnesota. NIBRT, Ireland’s National Institute for Bioprocessing Research and Training, published its Mid-Year Training Catalogue for 2026 covering all training options for the remainder of the year and launched a Digital Academy delivering a structured digitalisation curriculum built specifically for biopharma. Fraunhofer IAP develops tailored yeast strains and scalable bioprocesses for the industrial bioeconomy and operates the Biocampus Multipilot facility in Straubing, Germany, a multi-purpose demonstration plant built specifically to bridge lab scale and industrial production.

The key directions of biologic scale-up centers are:

Shared pilot-plant access: operating physical testbed and pilot-plant facilities that a developer can access without building its own, de-risking the jump from lab to commercial scale.
Demonstration-scale process validation: running a process at demonstration scale to validate it works reliably before a larger capital commitment to full commercial-scale manufacturing.
Workforce training and digitalisation curricula: structured training programs — including on manufacturing digitalisation — that build the skilled workforce a scaled-up biomanufacturing sector needs.
National-security and public-investment-backed capacity: public-private funding structures, including national-security-linked investment, building shared capacity that benefits an entire domestic biomanufacturing sector rather than one company.

Sectoral value chain#

[Lab-scale process development] ──> [Pilot-scale testbed access] ──> [Demonstration-scale validation]
                                                                    │
                                                        (Workforce training & digitalisation)
                                                                    │
                    [Commercial-scale readiness] <──── [Tech-transfer to commercial facility] <─── [Process data package compilation]

Fig. 1— Sectoral value chain

Value chain levels#

Level	Description	Key inputs/outputs
Lab-scale process development	Developing the biologic manufacturing process at lab bench scale.	In: Lab-scale process protocol. Out: Candidate process ready for scale-up.
Pilot-scale testbed access	Accessing a shared pilot-plant facility to run the process at pilot scale.	In: Candidate process ready for scale-up. Out: Pilot-scale run data.
Demonstration-scale validation	Running the process at demonstration scale to validate reliability before commercial commitment.	In: Pilot-scale run data. Out: Demonstration-scale validation data.
Process data package compilation	Compiling the pilot and demonstration data into a technology-transfer package.	In: Demonstration-scale validation data. Out: Technology-transfer data package.
Tech-transfer to commercial facility	Transferring the validated process to a dedicated commercial-scale manufacturing facility.	In: Technology-transfer data package. Out: Commercial-facility process transfer.
Commercial-scale readiness	Confirming the process runs reliably at full commercial scale, informed by the earlier pilot/demonstration work.	In: Commercial-facility process transfer. Out: Commercial-scale production readiness.

Table 1— Value chain levels

Cross-cutting technologies of the sector:

Pilot- and demonstration-scale biomanufacturing: shared testbed and pilot-plant facilities that let a biologic developer run small-batch production at pilot or demonstration scale before committing capital to a dedicated commercial-scale facility.
Public-private manufacturing-innovation institutes: consortia combining government, industry and academic funding to build and operate shared biomanufacturing testbeds, training programs and scale-up facilities that no single company would build alone.

02US#

The United States hosts two federally-linked manufacturing-innovation institutes building shared biomanufacturing capacity across a national facility network.

NIIMBL’s end-to-end testbed enhancement, BioMADE’s national pilot-plant network#

NIIMBL: announced 8 new technology and workforce projects in May 2026, including an enhanced end-to-end manufacturing testbed for fast, flexible drug-substance manufacturing.
BioMADE: expanded its biomanufacturing pilot-plant network with a new $40M Iowa facility (its third nationally) and finalized a $132M national-security-linked investment in a demonstration-scale facility in Minnesota.

03CN#

China is covered qualitatively rather than by a live-screened Chinese institute: candidate Chinese biologic scale-up centers searched during this screen returned no confirming 2026 source, so no Chinese institute is tabled below. Chinese biologic developers typically scale up through domestic CDMO capacity or university-affiliated pilot facilities rather than a confirmed distinct public-private scale-up institute of this type.

No confirmed domestic scale-up institute of this type; CDMO capacity and university pilot facilities cover the gap#

CDMO and university pilot facilities: Chinese biologic developers typically access pilot-scale capacity through domestic CDMOs or university-affiliated facilities rather than a confirmed distinct public-private manufacturing-innovation institute.
Domestic gap: no China-headquartered institute of this specific public-private scale-up-center type confirmed by a live 2026 source was found during this screen.

04EU#

Ireland and Germany host leading European biomanufacturing training and scale-up institutes, spanning workforce development to pilot-plant infrastructure.

NIBRT’s digitalisation curriculum, Fraunhofer IAP’s Biocampus Multipilot facility#

NIBRT: published its Mid-Year Training Catalogue for 2026 and launched a Digital Academy delivering a structured digitalisation curriculum built specifically for biopharma manufacturing.
Fraunhofer IAP: develops tailored yeast strains and scalable bioprocesses for the industrial bioeconomy and operates the Biocampus Multipilot demonstration plant in Straubing, built specifically to bridge lab scale and industrial production.

05Leading companies and research institutes#

Company / Institute	Country	Key products / platforms	Tech features	Status 2026
NIIMBL	🇺🇸 USA	End-to-end manufacturing testbed	8 new 2026 technology/workforce projects	research
BioMADE	🇺🇸 USA	National pilot-plant network	$40M Iowa + $132M Minnesota facilities	research
NIBRT	🇮🇪 Ireland	Training catalogue, Digital Academy	Structured biopharma digitalisation curriculum	research
Fraunhofer IAP	🇩🇪 Germany	Biocampus Multipilot facility	Lab-to-industrial-scale demonstration plant	research

Table 2— Leading companies and research institutes

06Tech stack and innovations#

The biologic scale-up center technology stack combines shared physical infrastructure with an emerging digitalisation and workforce layer:

Shared testbed infrastructure investment:
- BioMADE’s $40M and $132M facility investments show public-private capital building shared pilot and demonstration capacity at a scale few single companies would fund alone.
End-to-end testbed enhancement:
- NIIMBL’s 2026 testbed enhancement targets fast, flexible drug-substance manufacturing with state-of-the-art process equipment, sensors and controls.
Structured digitalisation training:
- NIBRT’s Digital Academy delivers a curriculum specifically built to prepare a biopharma manufacturing workforce for digitalized operations, not generic IT training.

07Value chains and production pipelines#

Industrial pipeline for biologic manufacturing scale-up#

┌───────────────────────────┐      ┌───────────────────────────┐
│ 1. Lab-scale process        │ ───> │ 2. Pilot-scale testbed      │
│    development                  │      │    access                        │
└───────────────────────────┘      └───────────────────────────┘
                                                 │
                                                 ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 4. Process data package     │ <─── │ 3. Demonstration-scale      │
│    compilation                  │      │    validation                     │
└───────────────────────────┘      └───────────────────────────┘
              │
              ▼
┌───────────────────────────┐      ┌───────────────────────────┐
│ 5. Tech-transfer to         │ ───> │ 6. Commercial-scale         │
│    commercial facility          │      │    readiness                      │
└───────────────────────────┘      └───────────────────────────┘

Fig. 2— Industrial pipeline for biologic manufacturing scale-up

Stage 1: Lab-scale process development

The biologic manufacturing process is developed at lab bench scale before any pilot-facility engagement.

Stage 2: Pilot-scale testbed access

The developer accesses a shared pilot-plant facility to run the process at pilot scale.

Stage 3: Demonstration-scale validation

The process is run at demonstration scale to validate reliability before a larger capital commitment.

Stage 4: Process data package compilation

Pilot and demonstration-scale data are compiled into a technology-transfer package.

Stage 5: Tech-transfer to commercial facility

The validated process is transferred to a dedicated commercial-scale manufacturing facility.

Stage 6: Commercial-scale readiness

The process is confirmed to run reliably at full commercial scale, informed directly by the earlier pilot and demonstration work.

Supplier	Region & tags
NIIMBL	US
BioMADE	US
NIBRT	EU
Fraunhofer IAP	EU

AI Recommendation

Key directions:

Shared pilot-plant access — physical testbed and pilot-plant facilities a developer can access without building its own.
Demonstration-scale process validation — running a process at demonstration scale before a larger capital commitment.
Workforce training and digitalisation curricula — structured training programs building the skilled workforce a scaled-up sector needs.
National-security and public-investment-backed capacity — public-private funding building shared capacity that benefits an entire domestic sector.

Market context:

These are public-private manufacturing-innovation institutes, not conventional for-profit vendors – the table lists them the same way other research-institute suppliers on this platform are listed, since they charge for facility/training access even though they are mission-driven, not shareholder-owned.
BioMADE’s Minnesota investment being explicitly linked to national security reflects a broader policy trend of treating domestic biomanufacturing capacity as strategic infrastructure, not just an industrial-policy nicety.
The jump from lab bench to commercial-scale manufacturing is one of the highest-attrition steps in biologic development – these centers exist specifically to de-risk that step for companies that can’t afford to build and validate their own pilot line.

Companies not in table: CPI (UK, Centre for Process Innovation) was searched but returned no confirming 2026 source specific to bioprocess scale-up, so it was dropped rather than tabled from general knowledge – it is a plausible player in this space.

Processing note: no Chinese-headquartered institute of this specific public-private type cleared the confirmation bar on this screen – the China section describes access via domestic CDMO capacity or university-affiliated pilot facilities instead.

Category boundary: this is distinct from CDMO/CRO contract-manufacturing articles elsewhere on this platform – those are commercial manufacturing-services vendors that run production for a fee; these institutes are shared, often subsidized testbeds whose primary purpose is de-risking scale-up and building sector-wide workforce capacity, not standing commercial production.